New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
16:13 EDTQGENQIAGEN announces three separate agreements to add biomarkers
QIAGEN announced three separate agreements that add multiple biomarkers to QIAGEN's development pipeline of diagnostics for Personalized Healthcare applications. QIAGEN intends to develop new diagnostics to guide treatment decisions, including companion diagnostics paired with medicines, based on these biomarkers. Most of these assays will be designed to run on the QIAsymphony RGQ modular laboratory workflow automation system as well as QIAGEN's next-generation sequencing workflows currently in development. QIAGEN has made a strategic equity investment in Drug Response Dx GmbH with the option to obtain worldwide rights to biomarkers for evaluation of rheumatoid arthritis patients to guide treatment with TNF-alpha inhibitors, which are widely prescribed for treatment of RA. QIAGEN has agreed to license exclusive worldwide rights from Insight Genetics for the RET, ROS1 and DEPDC1 biomarkers for use in non-small cell lung cancer, the most common form of lung cancer. QIAGEN Marseille has licensed exclusive worldwide rights to a biomarker for mutations of the HSP110 gene, which allows for identification of specific types of colorectal cancer, from InsermTransfert, the technology transfer arm of the French National Institute of Health and Medical Research.
News For QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
16:14 EDTQGENQIAGEN sees Q1 adjusted EPS 22c-23c, consensus 25c
Subscribe for More Information
16:13 EDTQGENQIAGEN sees adjusted sales, EPS growing at constant exchange rates
Subscribe for More Information
16:11 EDTQGENQIAGEN reports Q4 adjusted EPS 25c, consensus 30c
Subscribe for More Information
15:37 EDTQGENNotable companies reporting after market close
Subscribe for More Information
08:13 EDTQGENQIAGEN management to meet with Evercore ISI
Subscribe for More Information
January 27, 2015
16:06 EDTQGENQIAGEN launches monitor to track immune function in organ transplant patients
QIAGEN N.V. announced the commercial launch of QuantiFERON Monitor, a diagnostic for monitoring immune function. QIAGEN is launching QuantiFERON Monitor in Europe as a CE-marked in-vitro diagnostic. Primary applications include monitoring of immune function in solid organ transplant recipients. In North America and other markets, QFM is available for research use as an accurate marker of immune function in studies of immunosuppressive conditions, immune modulating therapies and recovery following transplantation.
15:04 EDTQGENQIAGEN management to meet with Leerink
Meeting to be held in New York on February 3 hosted by Leerink.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use